Completed PHASE4 INTERVENTIONAL 2-arm NCT02622022

Palliation of Dyspnea With Morphine in Patients With Interstitial Lung Disease (MORPHILD)

Sponsor: Skanderbog Apotek

Conditions Dyspnea Interstitial Lung Disease Morphine

Interventions Morphine hydrochloride Placebo

Updated 6 times since 2017 Last updated: Apr 8, 2019 Started: Jan 31, 2016 Primary completion: Feb 6, 2019 Completion: Feb 6, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Dyspnea and Interstitial Lung Disease, this trial is completed. The trial is conducted by Skanderbog Apotek and has accumulated 6 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
May 2019 — Jan 2021 [monthly]

Completed PHASE4

Status: Recruiting → Completed
Jun 2018 — May 2019 [monthly]

Recruiting PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE4

First recorded

Jan 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Skanderbog Apotek
University of Aarhus

Data source: University of Aarhus

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Aarhus C, Denmark